Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

682
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
682
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

419
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
419
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

443
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
443
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

538
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
538
Hormonal Control of the Ovarian Cycle01:30

Hormonal Control of the Ovarian Cycle

6.4K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle.  At puberty, GnRH secretion increases in both frequency and...
6.4K
Aromatic Hydrocarbon Cations: Structural Overview01:18

Aromatic Hydrocarbon Cations: Structural Overview

3.6K
Cycloheptatriene is a neutral monocyclic unsaturated hydrocarbon that consists of an odd number of carbon atoms and an intervening sp3 carbon in the ring. The three double bonds in the ring correspond to 6 π electrons, which is a Huckel number, and therefore satisfies the criteria of 4n + 2 π electrons. However, the intervening sp3 carbon disrupts the continuous overlap of p orbitals. As a result, cycloheptatriene is not aromatic.
Removing one hydrogen from the intervening CH2 group...
3.6K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Prevalence of Point-of-Care Ultrasound Abnormalities and Raised Serum NT-proBNP in Early-Onset Preeclampsia.

Anesthesia and analgesia·2025
Same author

Kisspeptin signalling and its correlation with placental ultrastructure and clinical outcomes in pregnant South African women with obesity and gestational diabetes.

Placenta·2024
Same author

Cardiometabolic Health in Pregnancy and Postpartum: Findings From a Prospective Cohort Study in South Africa.

Open forum infectious diseases·2024
Same author

Associations of HIV and antiretroviral therapy with gestational diabetes in South Africa.

AIDS (London, England)·2023
Same author

The FIGO Ovulatory Disorders Classification System.

Fertility and sterility·2022
Same author

The FIGO ovulatory disorders classification system.

International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics·2022

相关实验视频

Updated: Jan 10, 2026

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome
08:20

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

Published on: October 2, 2018

11.8K

赛普罗特酸用于 hirsutism 的治疗.

Mushi J Matjila1, Paul Andre Le Roux2, Zephne M van der Spuy1

  • 1Department of Obstetrics and Gynaecology, Faculty of Health Sciences, University of Cape Town, Groote Schuur Hospital, Cape Town, South Africa.

The Cochrane database of systematic reviews
|November 25, 2025
PubMed
概括

乙酸 (CPA) 与乙乙醇是一种常见的治疗 hirsutism,但证据表明,与其他药物比如 spironolactone 或 finasteride 相比,有效性的差异有限. 需要更多的研究来比较各种 hirsutism 治疗的安全性和有效性.

科学领域:

  • 内分泌学 在内分泌学.
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 头发,一个常见的内分泌问题,导致女性的头发过度生长,通常是管理的cyproterone乙酸 (CPA) 和ethinylestradiol.
  • 这篇综述是对先前关于CPA治疗 hirsutism的研究的更新,该研究于2003年首次发表.

研究的目的:

  • 评估单独使用或与乙烯乙 (ethinylestradiol) 结合使用的托酸 (CPA) 治疗 hirsutism 的益处和危害.
  • 为了比较CPA与其他药物的有效性,在减少头发生长和改善内分泌特征的女性与 hirsutism.

主要方法:

  • 进行了对多个数据库的系统搜索,查找随机对照试验 (RCT) 到2022年12月.
  • 包括涉及生育年龄的女性具有异常性 hirsutism 或 hirsutism 二次性卵巢高雄性质 (费里曼·盖尔威分数> 7) 的RCT.
  • 分析了主要结果,如临床参数 (FG分数,头发生长) 和二次结果,包括内分泌标志物和副作用.

主要成果:

  • 在比较不同剂量的CPA与乙烯雌二醇时,在症得分 (FG) 和自由水平上发现了有限的差异.
  • 乙酸 (CPA) 加上乙烯基二醇在降低 hirsutism 方面显示出与费纳斯特,螺旋和可纳相似的疗效,一些证据表明比弗卢胺有轻微的优势.
  • 有证据表明,CPA加乙inylestradiol在与乙inylestradiol相结合时,与费纳斯特或螺旋龙相比,在疗效方面几乎没有差异,尽管一些比较显示出不确定性.

更多相关视频

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.5K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

47.4K

相关实验视频

Last Updated: Jan 10, 2026

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome
08:20

A Hyperandrogenic Mouse Model to Study Polycystic Ovary Syndrome

Published on: October 2, 2018

11.8K
Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.5K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

47.4K

结论:

  • 虽然在CPA和特定药物 (如螺旋和芬胺) 之间观察到一些临床结果的差异,但在许多比较中,整体临床差异并不显著.
  • 小规模的研究和不一致的评估方法限制了关于不同治疗 hirsutism 的比较疗效和安全性的最终结论.
  • 需要进行更大规模,更精心设计的研究,以彻底比较可用的治疗选择的有效性和安全性概况.